Ashe Andrew D. 4

4 · Verve Therapeutics, Inc. · Filed Aug 29, 2022

Form 4

Period: 2022-08-25

See Remarks

Transactions

Exercise/Conversion
Common Stock
2022-08-25$2.87/sh+10,835$31,096→ 266,509 total
Exercise/Conversion
Common Stock
2022-08-25$1.48/sh+33,749$49,949→ 255,674 total
Exercise/Conversion
Common Stock
2022-08-25$1.39/sh+51,203$71,172→ 221,925 total
Exercise/Conversion
Stock Option (right to buy)
2022-08-25−51,203→ 0 total
Exercise: $1.39Exp: 2028-11-07→ Common Stock (51,203 underlying)
Exercise/Conversion
Stock Option (right to buy)
2022-08-25−10,835→ 153,278 total
Exercise: $2.87Exp: 2030-09-15→ Common Stock (10,835 underlying)
Exercise/Conversion
Stock Option (right to buy)
2022-08-25−33,749→ 26,999 total
Exercise: $1.48Exp: 2029-09-16→ Common Stock (33,749 underlying)

Footnotes (3)

[F1]The remaining shares underlying this option, which was granted on November 8, 2018, were fully vested as of August 20, 2022.
[F2]The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until July 26, 2023.
[F3]The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.

Documents

1 file